INITIAL TARGETS: MACULAR DEGENERATION AND GLAUCOMA


Macular degeneration is the leading cause of visual loss in the elderly, profoundly affecting their quality of life. Glaucoma affects millions of Americans and contributes to over 120,000 new cases of blindness each year—and is the leading cause of blindness among African-Americans. LEITR’s initial research platforms will explore the leading causes of these two blinding diseases, providing diseased or compromised eyes for advancing research in these important areas. LEITR research will drive the development of new diagnostic tests and pharmacologic treatments for delaying, arresting, and preventing progression of these devastating blinding diseases.

“THROUGH LEITR, WE WILL NOW HAVE AN UNPRECEDENTED ABILITY TO ACCESS OCULAR TISSUE WHICH WILL UNDOUBTEDLY FACILITATE NEW DISCOVERIES AND FUTURE THERAPIES.”

–MARK S HUMAYUN, MD, PHD
Cornelius Pings Professor of Biomedical Sciences Professor of Ophthalmology, Biomedical Engineering, Cell and Neurobiology Doheny Eye Institute, University of Southern California